Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer
AACHEN, Germany, 22 November 2022 – As CCO of Grünenthal, Janneke van der Kamp will be responsible for the entire Global Commercial Organisation and serve as a member of the Corporate Executive Board. Her focus will be to continue to grow the company’s key brands, prepare for the launch of Grünenthal’s pipeline assets and maximise the portfolio of established medicines.
“Grünenthal is a company with an excellent commercial performance and a compelling vision of a World Free of Pain”, says Janneke van der Kamp. “I am looking forward to meeting the teams around the world and together drive the growth of Grünenthal’s portfolio and prepare to bring new medicines to patients.”
Janneke van der Kamp succeeds Grünenthal’s current CCO, Mark Fladrich, who will retire from Grünenthal effective 28 February 2023. Over the past five years, Mark Fladrich has transformed Grünenthal’s commercial organisation. Key achievements included attracting and developing talents and the creation of a strong, patient and customer-oriented culture to support Grünenthal's vision of a World Free of Pain. Under his leadership, the European and Latin American businesses have been transformed, and Grünenthal has successfully entered the US market. The Grünenthal product portfolio has consistently grown which has contributed to the company’s strong profit growth over the last five years.
“With Janneke, we gain an exceptional leader with an excellent track record of developing high-performing, diverse teams and launching industry-leading brands. We are excited to welcome her to the team,” says Gabriel Baertschi, Chief Executive Officer Grünenthal.
“I want to thank Mark for everything he has done for Grünenthal, our portfolio and our people. His leadership, counsel and character will be missed. I wish him and his family all the best for the future.”
More information: www.grunenthal.com
Click here for our Grünenthal Report 2021/2022
Head of External Communication
Phone: +49 241 569-3269
Head Global Communication
About Grünenthal Group
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.
Subscribe to releases from Grünenthal Group
Subscribe to all the latest releases from Grünenthal Group by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Grünenthal Group
Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration2.8.2023 10:36:38 EEST | Press release
The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and intends to acquire the remaining share at the beginning of 2026 Aachen, Germany and Tokyo, Japan, 2 August 2023 – Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio. The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation,
Grünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee22.5.2023 11:57:05 EEST | Press release
Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis. The U.S. Food and Drug Administration’s Breakthrough Therapy Designation process aims to expedite the development of investigational medicines intended to treat severe conditions and where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on clinically significant endpoints. Aachen, Germany, 22 May 2023 – Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoa
Grünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research27.4.2023 09:00:00 EEST | Press release
Grünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal1.3.2023 12:54:00 EET | Press release
Aachen, Germany, 1st March 2023 – Janneke van der Kamp has today assumed her role as the new Chief Commercial Officer (CCO) of Grünenthal. She joins Grünenthal’s executive board and is responsible for the entire Global Commercial Organisation.
Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain18.8.2022 14:20:25 EEST | Press release
Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine. The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. Globally, more than 300 million patients suffer from osteoarthritis. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025. Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme wi